Logo-jrip
Submitted: 17 Jul 2023
Accepted: 26 Sep 2023
ePublished: 02 Oct 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2023;12(4): e32245.
doi: 10.34172/jrip.2023.32245

Scopus ID: 85174734228
  Abstract View: 574
  PDF Download: 593

Mini-Review

Possible amelioration impact of sodium-glucose cotransporter 2 inhibitors on cisplatin-induced renal toxicity; a mini-review on recent findings

Parisa Keshtgar 1 ORCID logo, Leila Mahmoodnia 2 ORCID logo, Samin Karamian 3* ORCID logo

1 Rural Health Services Center, Mashhad, Iran
2 Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 Emergency Department, Parsian Hospital, Shahrekord, Iran
*Corresponding Author: Samin Karamian, Email: karamian.samin@yahoo.com

Abstract

Cisplatin-induced nephrotoxicity is a crucial concern in cancer patients, limiting the dose and duration of cisplatin therapy. Several mechanisms contribute to cisplatin nephrotoxicity, including oxidative stress, inflammation, and mitochondrial dysfunction. SGLT2 inhibitors have emerged as a promising therapeutic option for various renal disorders due to their ability to restore renal homeostasis and mitigate renal injury

Implication for health policy/practice/research/medical education:

Cisplatin is a broadly administered chemotherapeutic compound for the treatment of several solid tumors; though, its use is frequently limited due to the development of nephrotoxicity. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs utilized to treat type 2 diabetes by inhibiting the SGLT2 accountable for glucose reabsorption in the kidneys. These inhibitors have also shown promise in improving renal function following administration of cisplatin, a commonly used chemotherapeutic drug that can cause kidney damage.

Please cite this paper as: Keshtgar P, Mahmoodnia L, Karamian S. Possible amelioration impact of sodium-glucose cotransporter 2 inhibitors on cisplatin-induced renal toxicity; a mini-review on recent findings. J Renal Inj Prev. 2023; 12(4): e32245. doi: 10.34172/jrip.2023.32245.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 575

Your browser does not support the canvas element.


PDF Download: 593

Your browser does not support the canvas element.